brca1 Mutation CarrierNCT01097278
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
A study testing cholecalciferol in people with brca1 Mutation Carrier and brca2 Mutation Carrier, run by SWOG Cancer Research Network at 360 sites in United States.
Trial summary
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- What is being tested?
- cholecalciferol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 208 participants
- Where
- 360 sitesUnited States
- Study dates
- 1 Nov 2011to Sep 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
DISEASE CHARACTERISTICS:
- At an elevated risk of breast cancer by at least one of the following criteria:
- Diagnosis of ADH, ALH, lobular carcinoma in situ (LCIS) or resected ductal carcinoma in situ (DCIS) or small invasive breast cancers (pTmi or pT1a N0) if no pior RT, tamoxifen, or systemic breast cancer treatment within 28 days prior to registration OR diagnosis of resected Stage I (T1b-c N0-N1mi) through Stage II breast cancer for which the participant has been disease-free for at least 5 years and has completed all adjuvant treatment OR
- A known* deleterious mutation in BRCA1, BRCA2, PTEN, or TP53 NOTE: *The participant must be a documented carrier to meet this criterion. If there is a known mutation in a hereditary breast cancer susceptibility gene in a participant's family member, the participant herself must have undergone genetic testing as per NCCN clinical guidelines to be eligible per this criterion.
- Modified Gail Model/CARE model** risk at 5 years ≥ 1.67% or lifetime risk ≥ 20% by Claus, BRCAPro, Tyrer-Cuzick or IBIS models OR
- Mammographic density ≥ 50% (heterogenously dense) NOTE: **Risk models are to be used only if there is no known previous diagnosis of resected DCIS or LCIS and there is no known deleterious mutation in BRCA1, BRCA2, PTEN, or TP53.
- At least one breast available for imaging and biopsy (a previously irradiated breast [i.e., for resected DCIS] is not evaluable for breast imaging or biopsy)
- Baseline mammogram (performed within 10 days after starting their last menstrual period on a digital mammography machine) that shows either normal or benign findings
- Baseline mammographic density > 10% based upon the classification system (2 = 11-50%, "scattered fibroglandular densities"; 3 = 51-75%, "heterogeneously dense"; 4 = >75, "extremely dense". Women with a baseline mammographic density of ≤ 10% (1 = ≤ 10% breasts are almost entirely fat)will not be eligible.
PATIENT CHARACTERISTICS:
- Premenopausal, defined as ≥ 1 of the following criteria:
- Less than 6 months since the last menstrual period, no prior bilateral oophorectomy, and no use of hormone-replacement therapy
- Has undergone a prior hysterectomy but no prior bilateral oophorectomy AND follicle-stimulating hormone values measured within the past 28 days are consistent with the normal values for the premenopausal state
- Zubrod performance status 0-1
- Serum creatinine ≤ upper limit of normal (ULN)
- Serum calcium or corrected calcium ≤ ULN
- Spot urine calcium:creatinine ratio < 0.37 mg/dL
- INR ≤ 1.5 times ULN+
- PT and PTT ≤ ULN*
- Baseline serum 25(OH)D level ≤ 32 ng/mL (or 80 nmol/L)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other prior malignancy except for the following:
- Adequately treated basal cell or squamous cell skin cancer
- In situ cervical cancer
- Adequately treated stage I or II (including resected Stage I, T1b-c N0-N1mi through Stage II breast cancer) from which the participant is currently in complete remission
- Any other cancer (including contralateral breast) for which the participant has been disease-free for ≥ 5 years
- No history of kidney stones
- No medical conditions requiring calcium or vitamin D supplementation (i.e., osteoporosis)
- No known hypersensitivity to vitamin D
- No known allergy to soy NOTE: +For patients undergoing breast biopsy.
PRIOR CONCURRENT THERAPY:
- Prior breast reduction surgery allowed
- No bilateral breast implants
- More than 1 month since prior surgery or radiotherapy to the breast for resected DCIS
- At least 28 days since prior tamoxifen
- Prior anticoagulant therapy allowed provided it is discontinued ≥ 7 days before breast biopsy
- No concurrent calcium or additional vitamin D supplements
- Concurrent multivitamins allowed provided that the dose of vitamin D in the multivitamin does not exceed 400 IU daily
- No concurrent participation in any other clinical trial for the treatment or prevention of cancer unless the participant is no longer receiving the intervention and is in the follow-up phase only (participants must not join such a trial while participating in this study)
Trial locations and contacts
360 sites in 1 country.
300 sites in 1 country
United States300 sites
Oncare Hawaii Inc-Pali Momi
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
Saint Anthony's Health
Alton, Illinois, 62002
Texas Tech University Health Science Center-Amarillo
Amarillo, Texas, 79106
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Alaska Regional Hospital
Anchorage, Alaska, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
AnMed Health Cancer Center
Anderson, South Carolina, 29621
AnMed Health Hospital
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
Northeast Alabama Regional Medical Center
Anniston, Alabama, 36202
Randolph Hospital
Asheboro, North Carolina, 27203
Hematology Oncology Associates of Central New York-Auburn
Auburn, New York, 13021
The Medical Center of Aurora
Aurora, Colorado, 80012
Hematology/Oncology Clinic LLP
Baton Rouge, Louisiana, 70809
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Billings Clinic Cancer Center
Billings, Montana, 59101
Montana Cancer Consortium NCORP
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Frontier Cancer Center and Blood Institute-Billings
Billings, Montana, 59102
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, 83712
Central Care Cancer Center-Carrie J Babb Cancer Center
Bolivar, Missouri, 65613
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Steward Saint Elizabeth's Medical Center
Brighton, Massachusetts, 02135
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Rocky Mountain Oncology
Casper, Wyoming, 82609
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California, 94546
Centralia Oncology Clinic
Centralia, Illinois, 62801
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Southern Oncology Specialists-Charlotte
Charlotte, North Carolina, 28262
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Riverside Methodist Hospital
Columbus, Ohio, 43214
Columbus NCI Community Oncology Research Program
Columbus, Ohio, 43215
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Doctors Hospital
Columbus, Ohio, 43228
John Muir Medical Center-Concord Campus
Concord, California, 94520
Mercy Hospital
Coon Rapids, Minnesota, 55433
Baptist Health Corbin
Corbin, Kentucky, 40701
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, 92627
Baylor University Medical Center
Dallas, Texas, 75246
Beaumont Hospital-Dearborn
Dearborn, Michigan, 48124
Dekalb Medical Center
Decatur, Georgia, 30033
Cancer Care Center of Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Heartland Cancer Research NCORP
Decatur, Illinois, 62526
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Delaware Radiation Oncology
Delaware, Ohio, 43015
Grady Memorial Hospital
Delaware, Ohio, 43015
Porter Adventist Hospital
Denver, Colorado, 80210
Colorado Blood Cancer Institute
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Colorado Cancer Research Program NCORP
Denver, Colorado, 80222
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Epic Care-Dublin
Dublin, California, 94568
Mercy Medical Center
Durango, Colorado, 81301
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic
Elkhart, Indiana, 46514-2098
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Comprehensive Cancer Care and Research Institute of Colorado LLC
Englewood, Colorado, 80113
Swedish Medical Center
Englewood, Colorado, 80113
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Botsford General Hospital
Farmington, Michigan, 48334
Hurley Medical Center
Flint, Michigan, 48502
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
McLeod Regional Medical Center
Florence, South Carolina, 29506
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Valley Medical Oncology Consultants-Fremont
Fremont, California, 94538
Unity Hospital
Fridley, Minnesota, 55432
Illinois CancerCare-Galesburg Cottage Plaza Office
Galesburg, Illinois, 61401
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Mountain Blue Cancer Care Center
Golden, Colorado, 80401
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Cone Health Cancer Center
Greensboro, North Carolina, 27403
Saint Francis Hospital
Greenville, South Carolina, 29601
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Greenwich Hospital
Greenwich, Connecticut, 06830
Rocky Mountain Cancer Centers-Greenwood Village
Greenwood Village, Colorado, 80111
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Saint Peter's Community Hospital
Helena, Montana, 59601
Hendersonville Hematology and Oncology at Pardee
Hendersonville, North Carolina, 28791
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Park Ridge Hospital Breast Health Center
Hendersonville, North Carolina, 28792
Hawaii Cancer Care Inc-POB II
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii, 96817
Hawaii Oncology Inc-Kuakini
Honolulu, Hawaii, 96817
Kuakini Medical Center
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
M D Anderson Cancer Center
Houston, Texas, 77030
The Methodist Hospital System
Houston, Texas, 77030
Southern Oncology Specialists-Huntersville
Huntersville, North Carolina, 28078
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Centerpoint Medical Center LLC
Independence, Missouri, 64057
Allegiance Health
Jackson, Michigan, 49201
Mercy Hospital-Joplin
Joplin, Missouri, 64804
Castle Medical Center
Kailua, Hawaii, 96734
Borgess Medical Center
Kalamazoo, Michigan, 49001
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Glacier Oncology PLLC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Providence Medical Center
Kansas City, Kansas, 66112
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology and Oncology Associates Incorporated
Kansas City, Missouri, 64118
Research Medical Center
Kansas City, Missouri, 64132
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
EvergreenHealth Medical Center
Kirkland, Washington, 98033
Community Howard Regional Health
Kokomo, Indiana, 46904
IU Health La Porte Hospital
La Porte, Indiana, 46350
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Saint Anthony Hospital
Lakewood, Colorado, 80228
Fairfield Medical Center
Lancaster, Ohio, 43130
Lancaster Radiation Oncology
Lancaster, Ohio, 43130
Carolina Blood and Cancer Care Associates PA-Lancaster
Lancaster, South Carolina, 29720
Sparrow Hospital
Lansing, Michigan, 48912
Doctor's Hospital of Laredo
Laredo, Texas, 78041
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Baptist Health Lexington
Lexington, Kentucky, 40503
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Liberty Radiation Oncology Center
Liberty, Missouri, 64068
Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii, 96766
Nebraska Cancer Research Center
Lincoln, Nebraska, 68510
Littleton Adventist Hospital
Littleton, Colorado, 80122
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Longmont United Hospital
Longmont, Colorado, 80501
Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado, 80501
Los Angeles County-USC Medical Center
Los Angeles, California, 90033
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
McKee Medical Center
Loveland, Colorado, 80539
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Novant Health Cancer Specialists-Matthews
Matthews, North Carolina, 28105
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho, 83642
Middlesex Hospital
Middletown, Connecticut, 06457
Mid-Michigan Medical Center - Midland
Midland, Michigan, 48670
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Winthrop University Hospital
Mineola, New York, 11501
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Trinity Cancer Care Center
Minot, North Dakota, 58701
Cancer Care Partners LLC
Mishawaka, Indiana, 46545
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Montana Cancer Specialists
Missoula, Montana, 59802
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Providence Hospital
Mobile, Alabama, 36608
Holy Family Medical Center
Monmouth, Illinois, 61462
Illinois CancerCare-Monmouth
Monmouth, Illinois, 61462
Lake Norman Hematology Oncology Specialists-Mooresville
Mooresville, North Carolina, 28117
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
El Camino Hospital
Mountain View, California, 94040
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112
Ochsner Medical Center Jefferson
New Orleans, Louisiana, 70121
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Columbia University/Herbert Irving Cancer Center
New York, New York, 10032
Licking Memorial Hospital
Newark, Ohio, 43055
Newark Radiation Oncology
Newark, Ohio, 43055
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Lakeland Community Hospital
Niles, Michigan, 49120
Community Cancer Center Foundation
Normal, Illinois, 61761
Mid-Illinois Hematology Oncology Associates Limited
Normal, Illinois, 61761
Highland General Hospital
Oakland, California, 94602
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Bay Area Tumor Institute
Oakland, California, 94609
Hematology and Oncology Associates-Oakland
Oakland, California, 94609
Tom K Lee Inc
Oakland, California, 94609
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Alegent Health Immanuel Medical Center
Omaha, Nebraska, 68122
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Alegent Health Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Providence Willamette Falls Medical Center
Oregon City, Oregon, 97045
Florida Hospital Orlando
Orlando, Florida, 32803
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Ottawa Regional Hospital and Healthcare Center
Ottawa, Illinois, 61350
Menorah Medical Center
Overland Park, Kansas, 66209
Saint Luke's South Hospital
Overland Park, Kansas, 66213
Parker Adventist Hospital
Parker, Colorado, 80138
Rocky Mountain Cancer Centers-Parker
Parker, Colorado, 80138
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Huntington Memorial Hospital
Pasadena, California, 91105
Singing River Hospital
Pascagoula, Mississippi, 39581
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Proctor Hospital
Peoria, Illinois, 61614
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare-Peru
Peru, Illinois, 61354
Phoenixville Hospital
Phoenixville, Pennsylvania, 19460
East Bay Medical Oncology Hematology Medical Associates Inc-Pleasant Hill
Pleasant Hill, California, 94523
Valley Medical Oncology Consultants
Pleasanton, California, 94588
Michiana Hematology Oncology PC-Plymouth
Plymouth, Indiana, 46563
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Saint Joseph Mercy Port Huron
Port Huron, Michigan, 48060
Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon, 97210
Providence Portland Medical Center
Portland, Oregon, 97213
Western Oncology Research Consortium
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Legacy Emanuel Hospital and Health Center
Portland, Oregon, 97227
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Kootenai Cancer Center
Post Falls, Idaho, 83854
Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas, 66208
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Princeton Community Hospital
Princeton, West Virginia, 24740
Saint Mary Corwin Medical Center
Pueblo, Colorado, 81004
Rocky Mountain Cancer Centers - Pueblo
Pueblo, Colorado, 81008
Annie Penn Memorial Hospital
Reidsville, North Carolina, 27320
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Highland Hospital
Rochester, New York, 14620
University of Rochester
Rochester, New York, 14642
Carolina Blood and Cancer Care Associates PA
Rock Hill, South Carolina, 29732
Highlands Oncology Group-Rogers
Rogers, Arkansas, 72758
Phelps County Regional Medical Center
Rolla, Missouri, 65401
Saint John's Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Hematology Oncology Associates of Central New York-Rome
Rome, New York, 13440
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Saint Mary's of Michigan
Saginaw, Michigan, 48601
Lakeland Hospital
Saint Joseph, Michigan, 49085
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Saint Joseph Oncology Inc
Saint Joseph, Missouri, 64507
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
About this study
Official title: Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women.
PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.
Read the detailed description
OBJECTIVES:
- To assess whether mammographic density is reduced in premenopausal women at high risk of breast cancer taking high-dose vitamin D3 (oral cholecalciferol 20,000 IU weekly) vs placebo for 1 year.
- To assess whether proliferation as measured by Ki-67 staining of breast epithelial cells is reduced in women receiving these treatments.
- To explore the difference in the expression of other biomarkers (including cleaved caspase-3 [apoptosis marker], ER, vitamin D receptor [VDR], and 1α-hydroxylase) in breast tissue obtained from these women.
- To assess whether parathyroid hormone, IGF-1, IGFBP-3, 25(OH)D, and 1,25(OH)D serum levels are altered in these women at baseline and at 6 and 12 months.
- To explore whether a change in mammographic density correlates with polymorphisms in the VDR gene.
- To assess other sources of vitamin D (sunlight exposure, diet) in these women using a validated questionnaire administered at baseline and at 12 and 24 months.
- To collect and bank serum, plasma, and breast tissue from these women before and after a 1-year intervention with vitamin D for future biomarker analysis.
- To assess the toxicity of high-dose cholecalciferol compared to placebo in this setting.
OUTLINE: This is a multicenter study. Participants are stratified according to baseline serum 25(OH)D level (< 20 ng/mL vs 20-32 ng/mL or < 50 nmol/L vs 50-80 nmol/L), baseline mammographic density (11-50% vs > 50%), and designated biopsy site (yes vs no). Participants are randomized to 1 of 2 treatment arms.
- Arm I: Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
- Arm II: Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
Blood samples are collected at baseline and periodically thereafter for biomarkers and 25(OH)D level. Participants undergo a mammogram at baseline and at 12 months. Participants may also undergo random core-needle breast biopsy at baseline and at 12 months.
Participants complete a questionnaire at baseline and at 12 and 24 months.
After completion of study therapy, participants are followed up at 1 and 12 months.
- Being tested
- cholecalciferol, placebo
- Keywords
- breast cancer, ductal breast carcinoma in situ, lobular breast carcinoma in situ, BRCA1 mutation carrier, BRCA2 mutation carrier
- Medical subject headings
- Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Breast Carcinoma In Situ
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cholecalciferolDietary supplement
Given orally
placeboOther
Given orally
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Experimental | Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity. Receives: Dietary Supplement: cholecalciferol |
| Arm II | Active comparator | Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity. Receives: Dietary Supplement: cholecalciferol; Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in mammographic density at 12 months compared to baseline
Measured: 12 months
Secondary outcomes (1)
Ki-67 as assessed in tissue obtained in breast biopsies at baseline and at 12 months
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2010 (estimated)
- Study start1 Nov 2011
- Primary completionAug 2017
- Study completionSep 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for brca1 Mutation CarrierStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Phase 2 study
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 208 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Katherine D. Crew, MD, MS, Principal investigator, Columbia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01097278
- Sponsor's protocol ID
- S0812
- Other IDs
- S0812, U10CA037429, NCI-2011-02032
- Status last verified
- Nov 2017
- First submitted
- 31 Mar 2010
- Last updated
- 24 Nov 2017
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
- ClinicalTrials.gov ID
- NCT01097278
- Acronym / sponsor ID
- S0812
- Keywords
- breast cancer, ductal breast carcinoma in situ, lobular breast carcinoma in situ, BRCA1 mutation carrier, BRCA2 mutation carrier
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 208 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 1 Nov 2011 (actual)
- Primary completion
- Aug 2017 (actual)
- Study completion
- Sep 2017 (actual)
- First posted
- 1 Apr 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women.
PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.
Detailed description
OBJECTIVES:
- To assess whether mammographic density is reduced in premenopausal women at high risk of breast cancer taking high-dose vitamin D3 (oral cholecalciferol 20,000 IU weekly) vs placebo for 1 year.
- To assess whether proliferation as measured by Ki-67 staining of breast epithelial cells is reduced in women receiving these treatments.
- To explore the difference in the expression of other biomarkers (including cleaved caspase-3 [apoptosis marker], ER, vitamin D receptor [VDR], and 1α-hydroxylase) in breast tissue obtained from these women.
- To assess whether parathyroid hormone, IGF-1, IGFBP-3, 25(OH)D, and 1,25(OH)D serum levels are altered in these women at baseline and at 6 and 12 months.
- To explore whether a change in mammographic density correlates with polymorphisms in the VDR gene.
- To assess other sources of vitamin D (sunlight exposure, diet) in these women using a validated questionnaire administered at baseline and at 12 and 24 months.
- To collect and bank serum, plasma, and breast tissue from these women before and after a 1-year intervention with vitamin D for future biomarker analysis.
- To assess the toxicity of high-dose cholecalciferol compared to placebo in this setting.
OUTLINE: This is a multicenter study. Participants are stratified according to baseline serum 25(OH)D level (< 20 ng/mL vs 20-32 ng/mL or < 50 nmol/L vs 50-80 nmol/L), baseline mammographic density (11-50% vs > 50%), and designated biopsy site (yes vs no). Participants are randomized to 1 of 2 treatment arms.
- Arm I: Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
- Arm II: Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
Blood samples are collected at baseline and periodically thereafter for biomarkers and 25(OH)D level. Participants undergo a mammogram at baseline and at 12 months. Participants may also undergo random core-needle breast biopsy at baseline and at 12 months.
Participants complete a questionnaire at baseline and at 12 and 24 months.
After completion of study therapy, participants are followed up at 1 and 12 months.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Randomized Phase 2 study
| Arm | Type | Receives |
|---|---|---|
| Arm I | Experimental | Dietary Supplement: cholecalciferolParticipants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity. |
| Arm II | Active comparator | Dietary Supplement: cholecalciferol, Other: placeboParticipants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cholecalciferolGiven orally | Dietary supplement | Arm I, Arm II |
| placeboGiven orally | Other | Arm II |
Primary outcome
Change in mammographic density at 12 months compared to baseline
Time frame: 12 months
1 secondary outcome
Ki-67 as assessed in tissue obtained in breast biopsies at baseline and at 12 months
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Nov 2017.
Related trials for brca1 Mutation Carrier
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingObservational study
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
Prostate Cancer
RecruitingPhase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS)
Active, not recruitingPhase 1
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
BRCA1/2 Mutation
Active, not recruiting
Prophylactic Salpingectomy With Delayed Oophorectomy
Ovarian Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katherine D. Crew, MD, MS principal investigator
Columbia University
360 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing cholecalciferol in people with brca1 Mutation Carrier and brca2 Mutation Carrier, run by SWOG Cancer Research Network at 360 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 360 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in mammographic density at 12 months compared to baseline (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2017.